PPD will apply its proprietary proteomics, peptidomics and metabolomics technology, which technology allows for the identification of biomarkers that may have a useful role in RCC detection and in the evaluation of therapeutic response.
Biomarkers are particular components of bodily fluids that are indicative of the progression or presence of disease.
RCC accounts for approximately three per cent of all adult malignancies and 90-95 per cent of all kidney cancers.
Approximately 35,710 new cases of RCC are diagnosed in the US each year with approximately 12,480 deaths.
RCC is an aggressive cancer, with a lack of early warning signs, diverse symptoms, resistance to radiation and chemotherapy, and infrequent responses to immunotherapy agents such as interferon alpha and interleukin (IL)-2.
At least four hereditary syndromes associated with renal cell carcinoma are currently known.
Although a variety of examinations such as computed tomography (CT), ultrasound and medical resonance imaging (MRI) are currently used to diagnose RCC, these are costly, time-consuming and often intrusive examinations.
At present, no accepted protocol has been developed for RCC screening among asymptomatic individuals in the general population and patients with a hereditary predisposition for RCC currently require periodic CT examinations.
A new diagnostic test would save money and could lead to more people being diagnosed at an earlier stage, thus improving survival rates.